Report Highlights

Hearing Screening Diagnostics in the U.S.: Market Overview

The U.S. hearing screening diagnostic devices market, which spans pure-tone audiometers, otoacoustic emission (OAE) screeners, automated auditory brainstem response (AABR) systems and tympanometers, was valued at USD 468 million in 2024. Demand splits along a clear public-private line. Newborn screening in hospital nurseries and neonatal intensive care units is almost entirely policy-driven through state mandates, while school, occupational and adult screening rests with private audiology practices, employers and retail clinics.

Policy has shaped the market's current form in two distinct ways. Section 399M of the Public Health Service Act authorised the CDC's Early Hearing Detection and Intervention (EHDI) programme, which funds state tracking and surveillance systems that make screening outcomes reportable. Product development, however, has been led by private manufacturers, with Natus Medical, Interacoustics and Welch Allyn commercialising devices cleared by FDA largely through 510(k) pathways rather than through government procurement.

Policy-Driven Growth in U.S. Hearing Screening Diagnostics

Three policy mechanisms drive device demand. First, state newborn hearing screening laws, which all 50 states have enacted, require universal screening before hospital discharge and fund follow-up through state EHDI programmes, converting every live birth into a recurring device purchase. Second, the Medicaid Early and Periodic Screening, Diagnostic and Treatment (EPSDT) mandate under Section 1905(r) of the Social Security Act obliges state Medicaid programmes to cover hearing screening for enrolled children, with federal matching funds underwriting the screening encounters.

Third, the Over-the-Counter Hearing Aid Act of 2017 directed FDA to create a regulated over-the-counter hearing aid category, which FDA finalised in August 2022 with the rule taking effect in October 2022. This pathway pushes consumers with mild-to-moderate loss toward self-assessment tools and, in many cases, pre-purchase screening, sending a portion of the population into diagnostic channels that previously went unmeasured. Growth therefore transfers from clinical gatekeepers to pharmacies, retail audiology and telehealth screening platforms.

Regulatory Barriers and Compliance Costs

FDA premarket review is the first barrier. Screening audiometers and OAE devices are Class II devices requiring 510(k) clearance under the Federal Food, Drug, and Cosmetic Act, and MDUFA V sets a 90-FDA-day performance goal for decisions on standard submissions. Manufacturers must also demonstrate conformance with IEC 60601-1 electrical safety requirements and, from 2 February 2026, comply with the Quality Management System Regulation under 21 CFR Part 820, which incorporates ISO 13485:2016. Compliance preparation for a mid-sized manufacturer typically runs to several hundred thousand dollars.

Reimbursement is the second barrier and sits with CMS. Medicare pays for diagnostic audiology under CPT codes such as 92551 for pure-tone screening and 92567 for tympanometry only when a physician orders the service for diagnosis, and routine hearing exams are excluded from Original Medicare coverage. State audiology licensure boards add a third layer: in many states, technicians can operate screeners only under supervision, limiting device use in unlicensed settings such as pharmacies.

Policy-Created Opportunities in U.S. Hearing Screening

Veterans Affairs procurement offers the largest near-term federal pipeline. VA's hearing health programme, which serves a population with substantial noise-induced hearing loss, buys screening and diagnostic equipment through Federal Supply Schedule contracts administered by the General Services Administration, giving manufacturers multi-year access to federal buyers without separate state tenders. Suppliers holding FSS contracts for audiometric equipment capture this demand directly.

CDC's EHDI tracking requirements create a second opportunity in data-linked devices. Because state programmes must link screening results to diagnosis and intervention records, manufacturers offering devices with integrated data export to state EHDI information systems and HL7-compliant electronic health records win hospital contracts. Natus Medical's and Interacoustics' interoperability features position them ahead of smaller entrants lacking connected products.

Market at a Glance

Leading Market Participants

• Natus Medical
• Interacoustics
• Demant
• Welch Allyn
• Maico Diagnostics
• Frye Electronics
• Intelligent Hearing Systems
• Otodynamics
• Grason-Stadler
• Otometrics

Regulatory and Policy Environment

The primary statutes are the Federal Food, Drug, and Cosmetic Act, whose Chapter V governs medical devices, and the Medical Device User Fee Amendments (MDUFA V), which fund FDA device review for fiscal years 2023 to 2027. FDA's Center for Devices and Radiological Health administers premarket review and quality system inspections, CMS sets reimbursement through the Medicare Physician Fee Schedule, and CDC's National Center on Birth Defects and Developmental Disabilities runs the EHDI programme. Key compliance requirements include 510(k) clearance, establishment registration and listing, and labelling under 21 CFR Part 801.

Upcoming changes are concrete. The amended Quality Management System Regulation takes effect on 2 February 2026, aligning FDA's quality system requirements with ISO 13485:2016, and MDUFA VI negotiations must conclude before the current authority expires on 30 September 2027. Against regional peers, the U.S. 510(k) route is faster than the EU Medical Device Regulation (Regulation (EU) 2017/745), where Class IIa devices require notified body certification, while Canada's Medical Devices Regulations (SOR/98-282) run a licence-based system with comparable technical requirements.

Long-Term Policy Outlook for U.S. Hearing Screening Diagnostics

MDUFA VI negotiations, which will precede the September 2027 expiry of MDUFA V, will set review goals and user fee levels for fiscal years 2028 to 2032 and will shape how quickly new screening algorithms reach the market. Congressional bills to add hearing coverage to Medicare Part B have been introduced across successive sessions without enactment, and their passage would convert routine adult screening from a self-paid service into a reimbursed one.

Two further shifts will reshape the market. OTC hearing aid sales will move screening volume toward retail and telehealth channels, creating demand for FDA-cleared self-test devices with clinical-grade sensitivity. Meanwhile, state newborn screening programmes will migrate tracking to interoperable data systems, reinforcing the advantage of manufacturers that already provide HL7-compatible devices and cloud-based reporting.